Last reviewed · How we verify
zidovudine + lamivudine + efavirenz
zidovudine + lamivudine + efavirenz is a Antiretroviral combination therapy (NRTI + NNRTI) Small molecule drug developed by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced patients.
This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes, preventing the virus from copying its genetic material and integrating into host cells.
This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes, preventing the virus from copying its genetic material and integrating into host cells. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | zidovudine + lamivudine + efavirenz |
|---|---|
| Sponsor | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
| Drug class | Antiretroviral combination therapy (NRTI + NNRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Zidovudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that compete with natural nucleotides to terminate viral DNA chain elongation. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that directly binds and inhibits reverse transcriptase. Together, this triple-drug regimen suppresses HIV viral load by targeting multiple steps of viral replication.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
Common side effects
- Dizziness and CNS effects
- Nausea
- Rash
- Headache
- Lipodystrophy
- Lactic acidosis
- Hepatotoxicity
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- A Prospective Cohort of Children With HIV Infection
- Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio (PHASE3)
- The Effect of Aspirin on HIV Disease Progression Among HIV- Infected Individuals Initiating Anti- Retroviral Therapy (PHASE2)
- Preventing Sexual Transmission of HIV With Anti-HIV Drugs (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- zidovudine + lamivudine + efavirenz CI brief — competitive landscape report
- zidovudine + lamivudine + efavirenz updates RSS · CI watch RSS
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran portfolio CI
Frequently asked questions about zidovudine + lamivudine + efavirenz
What is zidovudine + lamivudine + efavirenz?
How does zidovudine + lamivudine + efavirenz work?
What is zidovudine + lamivudine + efavirenz used for?
Who makes zidovudine + lamivudine + efavirenz?
What drug class is zidovudine + lamivudine + efavirenz in?
What development phase is zidovudine + lamivudine + efavirenz in?
What are the side effects of zidovudine + lamivudine + efavirenz?
What does zidovudine + lamivudine + efavirenz target?
Related
- Drug class: All Antiretroviral combination therapy (NRTI + NNRTI) drugs
- Target: All drugs targeting HIV reverse transcriptase
- Manufacturer: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced patients
- Compare: zidovudine + lamivudine + efavirenz vs similar drugs
- Pricing: zidovudine + lamivudine + efavirenz cost, discount & access